Phase 2, Single Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Grants and Contracts Details

StatusFinished
Effective start/end date11/12/07 → 4/30/12

Funding

  • AMGen: $35,012.00